Avenue Therapeutics
Biotechnology
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.

$4M

Market Cap • 12/30/2024

2015

(10 years)
Founded

2017

(8 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Bay Harbor Islands

Headquarters • Florida